Mobile

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Coli...

Update Il y a 4 ans
Reference: EUCTR2008-002782-32

A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

Primary Objective for the Induction Phase • To determine the effect of MLN0002 induction treatment on clinical response at 6 weeks Primary Objective for the Maintenance Phase • To determine the effect of MLN0002 maintenance treatment on clinical remission at 52 weeks

Inclusion criteria

  • Moderate to severe Ulcerative Colitis

Links